PharmaFocus Today – Page 4 – media

Xuesaitong soft capsules are the company’s exclusive core dosage form

January 14th – Kunming Pharmaceutical GroupIn response to investor inquiries on the interactive platform, the company stated that Xuesaitong soft capsules are its exclusive core dosage form. As a liquid dosage form, soft capsules offer faster absorption rates, and the simplified formulation and single excipient composition help optimize product safety from the source, creating a differentiated advantage. The company continues to explore the application of Xuesaitong soft capsules in precise indications and in combination with other drugs. Among these, the core product “Lixuwang” Xuesaitong soft capsules combined with aspirin in the integrated traditional Chinese and Western medicine treatment plan “Ali Therapy” has achieved good academic results. Simultaneously, leveraging its comprehensive R&D pipeline and technological reserves, the company continuously iterates and upgrades existing products to meet the medication needs of different patient groups and consolidate and enhance its long-term competitiveness. Furthermore, the company highly values the medication experience and needs of ...
- Source: drugdu
- 70
- January 15, 2026
Hualan Biological’s investee company’s application for marketing authorization of adalimumab injection has been accepted

On January 13, Hualan Biological Engineering Co., Ltd.The company issued an announcement regarding its investee company, Hualan Ankang Biotechnology Co., Ltd.The company (formerly known as Hualan Gene Engineering Co., Ltd.) has received the Acceptance Notice (Acceptance No.: CXSS2600006) from the National Medical Products Administration for its application for registration and marketing authorization of adalimumab injection for domestic production. This drug is a biosimilar used to treat various autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, and Crohn’s disease. The announcement stated that, as of now, Shenzhou Cell　　has [a certain number of] [products/services] in China.Adalimumab injection from eight companies, including an engineering company, has been approved for marketing. If Hualan Ankang’s product is ultimately approved for marketing, it will enrich its product portfolio and is expected to add a new profit growth point. https://finance.eastmoney.com/a/202601133616721398.html
- Source: drugdu
- 71
- January 15, 2026
Gan & Lee Pharmaceuticals’ glargine insulin injection receives marketing authorization from the European Commission

January 14th that Gan & Lee Pharmaceuticals…(603087) announced that the company and its wholly-owned European subsidiary, Gan & Lee Pharmaceuticals Europe Ltd., recently received a notification from the European Commission that the company’s product, insulin glargine injection (trade name: Ondibta), has obtained marketing authorization in the European Union, Iceland, Liechtenstein and Norway for the treatment of diabetes in adults, adolescents and children aged 2 years and older. https://finance.eastmoney.com/a/202601143619110685.html
- Source: drugdu
- 68
- January 15, 2026
Application for registration of erythromycin lactobionate for injection accepted

Fosun Pharma (600196) announced on January 14 that its subsidiary, Suzhou Erye Pharmaceutical Co., Ltd., has recently had its drug registration application for injectable erythromycin lactobionate accepted by the National Medical Products Administration. This drug is a chemical drug intended for use in treating infections caused by specific susceptible strains of microorganisms when oral administration is not feasible or the severity of the infection requires rapid attainment of high erythromycin serum concentrations; for the prevention of initial rheumatic fever; for the prevention of recurrence of rheumatic fever; and for the prevention of bacterial endocarditis. https://finance.eastmoney.com/a/202601143619173587.html
- Source: drugdu
- 74
- January 15, 2026
High-potency rabies vaccine completes Phase III clinical trials

On January 15, Aim Vaccine (06660) issued an announcement stating that its iterative process high-titer human diploid rabies vaccine has successfully completed Phase III clinical field work. This product demonstrated high levels of protective antibodies in animal trials, with a significantly higher potency than existing human diploid rabies vaccines. Compared to traditional first-generation human diploid rabies vaccines, the company’s vaccine has overcome technical bottlenecks such as low viral titer and low yield, optimized purification processes, and significantly improved product quality and safety. According to Frost & Sullivan, China’s rabies vaccine market is projected to reach RMB 14.8 billion by 2030. This vaccine offers flexible administration methods and has the capacity for large-scale production, making it expected to become the preferred choice for vaccination institutions, further solidifying the company’s market position and promoting sustainable development. https://finance.eastmoney.com/a/202601153619836997.html
- Source: drugdu
- 78
- January 15, 2026
First Dry Powder Inhaler from a Chinese Pharmaceutical Company Approved by FDA for U.S. Marketing

On January 12, 2026 (U.S. time), Runsheng Pharmaceutical Co., Ltd. (hereinafter referred to as “Runsheng Pharmaceutical”) announced exciting news: its submitted product Fluticasone Propionate and Salmeterol Inhalation Powder (USAN: Fluticasone Propionate and Salmeterol Inhalation Powder USP, ANDA No.: 214464) has officially obtained marketing approval from the U.S. Food and Drug Administration (FDA). This marks the first-ever FDA approval of a dry powder inhaler (DPI) independently developed by a Chinese pharmaceutical company, representing a pivotal breakthrough for China’s high-end complex drug formulations to penetrate the international mainstream market. Formulated as a fixed-dose combination therapy integrating a bronchodilator and an inhaled corticosteroid, this product is specifically indicated for the maintenance treatment of reversible airway obstructive diseases such as asthma in adults and pediatric patients. Picture source: Boteng Pharmaceuticals 01 Originator Background: The Market Foundation of a Multi-Hundred-Billion-Dollar Product The originator of this product is Advair® Diskus®, developed by the UK-based GlaxoSmithKline (GSK). ...
- Source: drugdu
- 79
- January 14, 2026
Sino Biopharmaceutical Acquires Hangzhou Hygieia Biomedical

On January 13, Hong Kong-listed pharmaceutical leader Sino Biopharmaceutical (1177.HK) issued an announcement, declaring the full acquisition of domestic siRNA innovative drug company Hangzhou Hygieia Biomedical for a total price of RMB 1.2 billion. According to available data, Hygieia Biomedical was established in 2018 and is committed to providing innovative siRNA products with ultra-long action and low dosage advantages. The core R&D team, led by founder and chief scientist Dr. Cui Kunyuan, possesses over 20 years of professional experience in the development of small nucleic acid drugs, securing more than 50 core patents covering multiple delivery systems. Leveraging this profound technical accumulation, Hygieia has established six major intrahepatic and extrahepatic delivery platforms. Currently, four innovative drug candidates have advanced into the clinical stage, with over 20 projects in the preclinical phase, and the company has achieved two external licensing agreements. These pipelines hold significant potential as global First-in-Class (FIC) and ...
- Source: drugdu
- 72
- January 14, 2026
U.S. FDA Accepts Investigational New Drug (IND) Application for LAE118

China Securities Intelligent Finance: Laekna, Inc. (02105.HK) announced on the morning of January 14 that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for LAE118, a novel pan-mutation selective PI3Kα inhibitor. The drug is intended for the treatment of patients with PIK3CA-mutated solid tumors. The company stated it will collaborate closely with regulatory authorities to advance the application and is committed to providing this precision therapy to cancer patients in need of new treatment options. LAE118 is a key candidate that the company is actively progressing into clinical research. https://finance.eastmoney.com/a/202601143618541346.html
- Source: drugdu
- 48
- January 14, 2026
Another boost to domestically developed vaccines! Baihui Biotechnology’s human diploid cell rabies vaccine approved for clinical trials

On January 12, 2026, the National Medical Products Administration (NMPA) officially issued a Clinical Trial Approval Notice (Acceptance No.: CXSL2500917, Registration Category 3.3) to Beijing Baihui Biotechnology Co., Ltd. and Bohui Biopharmaceutical Co., Ltd. for their jointly submitted freeze-dried human rabies vaccine (human diploid cell). This vaccine, incorporating multiple technological innovations, has successfully entered the clinical trial stage, marking a key breakthrough for Baihui Biotechnology in the field of viral vaccine development and providing a new localized solution for rabies prevention and control in my country. pictureRabies has a near 100% mortality rate, making prevention and control an urgent need. Rabies, an acute infectious disease of the central nervous system caused by the rabies virus, is a public health nightmare due to its lethality. Data shows that approximately 59,000 people die from the disease globally each year, with the majority of deaths occurring in developing countries. After onset, patients exhibit ...
- Source: drugdu
- 45
- January 14, 2026
Eli Lilly’s oral weight loss drug has been submitted for marketing approval in China

According to data from PharmNet, Eli Lilly has submitted a marketing application to the NMPA for orforglipron . Previously, at the end of 2025, Eli Lilly had submitted a New Drug Application (NDA) for the same drug to the U.S. FDA for the treatment of obesity or overweight in adults. Orforglipron (formerly known as OWL833) was first discovered by Chugai Pharmaceutical Co., Ltd. In September 2018, Chugai Pharmaceutical signed a global exclusive licensing agreement with Eli Lilly and Company, under which Eli Lilly and Company will obtain the global rights to develop and commercialize OWL833. According to the results of Eli Lilly’s Phase 3 clinical trial ATTAIN-2, orforglipron showed significant efficacy and a safety profile consistent with injectable GLP-1RA drugs. In obese or overweight participants with type 2 diabetes (a population that is more difficult to lose weight), during the 72-week treatment period, the mean weight loss was 10.4 kg ...
- Source: drugdu
- 45
- January 14, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.